The ELN classification (2010), recognized by the WHO, divides patients on the basis of CN-AML molecular alterations, namely NPM1, CEBPA, and FLT3 mutations (Döhner et al., 2010). This evidence concerns the gene NPM1 and acute myeloid leukemia.